Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:CRBU NASDAQ:OCS NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$9.18-2.1%$8.68$6.22▼$17.17$911.94M1.3340,742 shs3,162 shsCRBUCaribou Biosciences$2.63-1.5%$2.05$0.66▼$3.00$248.64M2.591.42 million shs668,132 shsOCSOculis$21.75+0.9%$18.05$14.00▼$23.08$940.92M0.2975,037 shs98,477 shsORKAOruka Therapeutics$27.48+3.5%$17.59$5.49▼$31.13$1.10B-0.29612,266 shs332,019 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+2.63%-3.50%+14.25%-16.92%+22.76%CRBUCaribou Biosciences-5.99%-2.91%+48.33%+30.24%+29.61%OCSOculis+0.89%+1.99%+22.03%+23.14%+51.02%ORKAOruka Therapeutics-4.84%+3.95%+78.26%+82.67%-8.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$9.18-2.1%$8.68$6.22▼$17.17$911.94M1.3340,742 shs3,162 shsCRBUCaribou Biosciences$2.63-1.5%$2.05$0.66▼$3.00$248.64M2.591.42 million shs668,132 shsOCSOculis$21.75+0.9%$18.05$14.00▼$23.08$940.92M0.2975,037 shs98,477 shsORKAOruka Therapeutics$27.48+3.5%$17.59$5.49▼$31.13$1.10B-0.29612,266 shs332,019 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group+2.63%-3.50%+14.25%-16.92%+22.76%CRBUCaribou Biosciences-5.99%-2.91%+48.33%+30.24%+29.61%OCSOculis+0.89%+1.99%+22.03%+23.14%+51.02%ORKAOruka Therapeutics-4.84%+3.95%+78.26%+82.67%-8.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMBGM Group 1.00SellN/AN/ACRBUCaribou Biosciences 2.50Moderate Buy$6.67153.49% UpsideOCSOculis 2.60Moderate Buy$41.0088.51% UpsideORKAOruka Therapeutics 2.83Moderate Buy$41.8052.11% UpsideCurrent Analyst Ratings BreakdownLatest CRBU, OCS, ORKA, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025ORKAOruka TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.0010/13/2025ORKAOruka TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$48.0010/8/2025BGMBGM GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025CRBUCaribou BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OCSOculisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$33.00 ➝ $51.0010/8/2025ORKAOruka TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$33.00 ➝ $36.009/29/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/27/2025BGMBGM GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025CRBUCaribou BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$25.10M35.56N/AN/A$7.34 per share1.25CRBUCaribou Biosciences$9.99M24.52N/AN/A$2.79 per share0.94OCSOculis$780K1,217.44N/AN/A$1.91 per share11.39ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACRBUCaribou Biosciences-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)OCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)Latest CRBU, OCS, ORKA, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025ORKAOruka Therapeutics-$0.57N/AN/AN/AN/AN/A11/6/2025Q3 2025OCSOculis-$0.50N/AN/AN/A$0.23 millionN/A11/5/2025Q3 2025CRBUCaribou Biosciences-$0.36N/AN/AN/AN/AN/A8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/12/2025Q2 2025CRBUCaribou Biosciences-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/A1.821.45CRBUCaribou BiosciencesN/A6.666.66OCSOculis0.014.554.55ORKAOruka TherapeuticsN/A27.4227.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/ACRBUCaribou Biosciences77.51%OCSOculis22.30%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%CRBUCaribou Biosciences8.28%OCSOculisN/AORKAOruka Therapeutics24.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/ACRBUCaribou Biosciences10093.12 million85.41 millionOptionableOCSOculis243.66 millionN/ANot OptionableORKAOruka TherapeuticsN/A41.54 million28.20 millionN/ACRBU, OCS, ORKA, and BGM HeadlinesRecent News About These CompaniesOruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at BarclaysOctober 14 at 8:01 AM | marketbeat.comBarclays Initiates Coverage of Oruka Therapeutics (ORKA) with Overweight RecommendationOctober 13, 2025 | msn.comOruka Therapeutics initiated with an Overweight at BarclaysOctober 13, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Trading Up 7.5% - Should You Buy?October 10, 2025 | marketbeat.comOruka Therapeutics (ORKA) Is Up 33.2% After Announcing $1.25B Shelf Registration and $200M OfferingOctober 10, 2025 | finance.yahoo.comWeiss Ratings Reiterates Sell (D-) Rating for Oruka Therapeutics (NASDAQ:ORKA)October 10, 2025 | marketbeat.comOruka Therapeutics files to sell 39.43M shares of common stock for holdersOctober 4, 2025 | msn.comBTIG Reiterates Oruka Therapeutics (ORKA) Buy RecommendationSeptember 29, 2025 | msn.comLeerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake newsSeptember 29, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - What's Next?September 29, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG ResearchSeptember 29, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from BrokeragesSeptember 28, 2025 | marketbeat.comQ3 EPS Forecast for Oruka Therapeutics Increased by AnalystSeptember 22, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Trading Down 6.2% - Here's What HappenedSeptember 20, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street ZenSeptember 20, 2025 | marketbeat.comOruka Therapeutics, Up 10%, Is Trying To Take On AbbVie's Biggest MoneymakerSeptember 19, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Expected to Rise, BTIG Research Analyst SaysSeptember 19, 2025 | marketbeat.comOruka Therapeutics presents positive interim phase 1 results for ORKA-001 at EADV CongressSeptember 18, 2025 | pharmabiz.comPOruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Still a Buy?September 18, 2025 | marketbeat.comOruka reveals $180M financing and late breaking psoriasis dataSeptember 18, 2025 | thepharmaletter.comTOruka Therapeutics stock surges after positive Phase 1 resultsSeptember 18, 2025 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBU, OCS, ORKA, and BGM Company DescriptionsBGM Group NASDAQ:BGM$9.18 -0.20 (-2.13%) Closing price 04:00 PM EasternExtended Trading$9.24 +0.06 (+0.71%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Caribou Biosciences NASDAQ:CRBU$2.63 -0.04 (-1.50%) Closing price 04:00 PM EasternExtended Trading$2.70 +0.07 (+2.66%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Oculis NASDAQ:OCS$21.75 +0.20 (+0.93%) Closing price 04:00 PM EasternExtended Trading$21.70 -0.05 (-0.23%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Oruka Therapeutics NASDAQ:ORKA$27.48 +0.92 (+3.46%) Closing price 04:00 PM EasternExtended Trading$27.47 -0.01 (-0.04%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
